WealthPlan Investment Management LLC bought a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 7,440 shares of the company’s stock, valued at approximately $377,000.
Several other large investors have also recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its position in shares of CRISPR Therapeutics by 16.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 118,444 shares of the company’s stock valued at $7,741,000 after purchasing an additional 16,669 shares in the last quarter. Continental Investors Services Inc. bought a new position in shares of CRISPR Therapeutics during the 3rd quarter valued at about $1,554,000. IHT Wealth Management LLC boosted its position in shares of CRISPR Therapeutics by 36.2% during the 3rd quarter. IHT Wealth Management LLC now owns 10,045 shares of the company’s stock valued at $656,000 after purchasing an additional 2,668 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of CRISPR Therapeutics by 0.9% during the 3rd quarter. California State Teachers Retirement System now owns 63,312 shares of the company’s stock valued at $4,137,000 after purchasing an additional 566 shares in the last quarter. Finally, Liberty One Investment Management LLC boosted its position in shares of CRISPR Therapeutics by 133.6% during the 3rd quarter. Liberty One Investment Management LLC now owns 3,912 shares of the company’s stock valued at $256,000 after purchasing an additional 2,237 shares in the last quarter. Institutional investors and hedge funds own 71.51% of the company’s stock.
Analyst Ratings Changes
Several research firms have recently weighed in on CRSP. Oppenheimer reduced their price objective on shares of CRISPR Therapeutics from $110.00 to $102.00 and set an “outperform” rating for the company in a research report on Thursday, February 23rd. Citigroup reduced their price objective on shares of CRISPR Therapeutics from $83.00 to $63.00 and set a “neutral” rating for the company in a research report on Wednesday, November 23rd. Morgan Stanley raised their target price on shares of CRISPR Therapeutics from $37.00 to $39.00 and gave the stock an “underweight” rating in a report on Monday, February 27th. Chardan Capital decreased their target price on shares of CRISPR Therapeutics from $153.00 to $123.00 and set a “buy” rating for the company in a report on Wednesday, February 22nd. Finally, EF Hutton Acquisition Co. I reiterated a “buy” rating and issued a $75.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, February 22nd. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $75.06.
CRISPR Therapeutics Stock Performance
CRSP stock opened at $45.74 on Friday. The stock has a market cap of $3.60 billion, a P/E ratio of -5.46 and a beta of 1.73. The firm has a 50 day simple moving average of $49.78 and a 200 day simple moving average of $53.79. CRISPR Therapeutics AG has a 52 week low of $38.94 and a 52 week high of $86.95.
CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last posted its quarterly earnings results on Tuesday, February 21st. The company reported ($1.41) EPS for the quarter, topping the consensus estimate of ($2.27) by $0.86. The business had revenue of $6.00 million during the quarter, compared to analysts’ expectations of $7.37 million. CRISPR Therapeutics had a negative net margin of 54,271.70% and a negative return on equity of 31.85%. The firm’s quarterly revenue was down 53.5% compared to the same quarter last year. During the same period last year, the company posted ($1.84) earnings per share. Sell-side analysts predict that CRISPR Therapeutics AG will post -7.54 EPS for the current year.
Insider Activity at CRISPR Therapeutics
In related news, CEO Samarth Kulkarni sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, January 27th. The shares were sold at an average price of $51.47, for a total transaction of $1,286,750.00. Following the transaction, the chief executive officer now owns 369,111 shares of the company’s stock, valued at $18,998,143.17. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders have sold 75,000 shares of company stock valued at $3,516,250. 5.30% of the stock is currently owned by corporate insiders.
CRISPR Therapeutics Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Read More
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating).
Receive News & Ratings for CRISPR Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRISPR Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
Read more here: Source link
